MX2017000331A - Compuestos de aminopiridazinona como inhibidores de quinasas de proteina. - Google Patents

Compuestos de aminopiridazinona como inhibidores de quinasas de proteina.

Info

Publication number
MX2017000331A
MX2017000331A MX2017000331A MX2017000331A MX2017000331A MX 2017000331 A MX2017000331 A MX 2017000331A MX 2017000331 A MX2017000331 A MX 2017000331A MX 2017000331 A MX2017000331 A MX 2017000331A MX 2017000331 A MX2017000331 A MX 2017000331A
Authority
MX
Mexico
Prior art keywords
protein kinase
kinase inhibitors
aminopyridazinone
compounds
aminopyridazinone compounds
Prior art date
Application number
MX2017000331A
Other languages
English (en)
Inventor
Zhang Minsheng
Liu Dong
Hu Qiyue
Original Assignee
Eternity Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eternity Bioscience Inc filed Critical Eternity Bioscience Inc
Publication of MX2017000331A publication Critical patent/MX2017000331A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings

Abstract

La presente descripción proporciona un compuesto de fórmula (I) y su uso para el tratamiento terapéutico de cánceres humanos incluyendo linfoma de células B y enfermedades autoinmunes tales como artritis reumatoide, lupus eritematoso sistémico y esclerosis múltiple.
MX2017000331A 2014-07-07 2014-10-20 Compuestos de aminopiridazinona como inhibidores de quinasas de proteina. MX2017000331A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462021421P 2014-07-07 2014-07-07
PCT/US2014/061393 WO2016007185A1 (en) 2014-07-07 2014-10-20 Aminopyridazinone compounds as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
MX2017000331A true MX2017000331A (es) 2017-08-25

Family

ID=55064639

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017000331A MX2017000331A (es) 2014-07-07 2014-10-20 Compuestos de aminopiridazinona como inhibidores de quinasas de proteina.

Country Status (15)

Country Link
US (2) US9951077B2 (es)
EP (1) EP3166608B1 (es)
JP (1) JP6409116B2 (es)
KR (1) KR102073797B1 (es)
CN (2) CN106573001B (es)
AU (1) AU2014400628B2 (es)
BR (1) BR112017000470B1 (es)
CA (1) CA2953798C (es)
ES (1) ES2706745T3 (es)
MX (1) MX2017000331A (es)
PL (1) PL3166608T3 (es)
RU (1) RU2674701C2 (es)
TW (1) TWI711619B (es)
WO (1) WO2016007185A1 (es)
ZA (1) ZA201700115B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106573001B (zh) * 2014-07-07 2019-01-29 江苏恒瑞医药股份有限公司 作为蛋白激酶抑制剂的氨基哒嗪酮化合物
CN105837576B (zh) * 2015-01-14 2019-03-26 湖北生物医药产业技术研究院有限公司 Btk抑制剂
RU2728827C2 (ru) * 2016-01-05 2020-07-31 Цзянсу Хэнжуй Медицин Ко., Лтд. Кристаллическая форма ингибитора тирозинкиназы брутона и способ её получения
CN107417687A (zh) * 2016-05-24 2017-12-01 中国科学院上海药物研究所 五元杂环并[3,4‑d]哒嗪酮类化合物、其制备方法、药物组合物及其应用
WO2017202343A1 (zh) * 2016-05-24 2017-11-30 中国科学院上海药物研究所 五元杂环并[3,4-d]哒嗪酮类化合物、其制备方法、药物组合物及其应用
JP6966044B2 (ja) * 2016-06-22 2021-11-10 シャンハイ フォチョン ファーマシューティカル カンパニー リミテッド タンパク質キナーゼ阻害剤としての置換されているピロロ［２，３−ｄ］ピリダジン−４−オン及びピラゾロ［３，４−ｄ］ピリダジン−４−オン
BR112019023632A2 (pt) * 2017-05-18 2020-08-18 Jiangsu Hengrui Medicine Co., Ltd. uso do inibidor de ezh2 combinado com o inibidor de btk na preparação de fármacos para tratamento de tumor
EP3650025A4 (en) 2017-07-04 2021-04-28 Jiangsu Hengrui Medicine Co., Ltd. PHARMACEUTICAL COMPOSITION AND METHOD FOR MANUFACTURING THEREOF
TW201908320A (zh) * 2017-07-14 2019-03-01 大陸商江蘇恆瑞醫藥股份有限公司 一種ｂｔｋ激酶抑制劑的結晶形式及製備方法
TW201943711A (zh) 2018-04-13 2019-11-16 大陸商江蘇恆瑞醫藥股份有限公司 一種吡咯並胺基噠嗪酮化合物的製備方法及其中間體
MA52780A (fr) 2018-06-11 2021-04-14 Amgen Inc Inhibiteurs de kras g12c pour le traitement du cancer
US20210253585A1 (en) * 2018-08-22 2021-08-19 Jiangsu Hengrui Medicine Co., Ltd. Preparation method of pyrrolo-amino-pyridazinone compound and intermediate thereof
CN111499642A (zh) * 2019-01-31 2020-08-07 江苏恒瑞医药股份有限公司 吡咯并[2,3-d]哒嗪-7-酮类衍生物的可药用盐、晶型及其制备方法
EP3977997A4 (en) 2019-05-31 2022-07-27 Jiangsu Hengrui Medicine Co., Ltd. SOLID DISPERSION AND PROCESS FOR PRODUCTION
CN110372562B (zh) * 2019-07-09 2021-04-06 上海再启生物技术有限公司 一种btk激酶抑制剂关键中间体的晶型及其制备方法
WO2021057998A1 (zh) * 2019-09-29 2021-04-01 上海森辉医药有限公司 一种吡咯并氨基哒嗪酮化合物的制备方法
CN112745255A (zh) * 2019-10-30 2021-05-04 江苏恒瑞医药股份有限公司 一种btk激酶抑制剂的制备方法
EP4193995A1 (en) * 2020-08-10 2023-06-14 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Use of btk inhibitors in the treatment of diseases
CN116096720A (zh) * 2020-08-27 2023-05-09 上海和誉生物医药科技有限公司 二氢吡咯并[2,3-d]哒嗪-7-酮衍生物，其制备方法和应用
US20220143026A1 (en) 2020-11-12 2022-05-12 Tg Therapeutics, Inc. Triple combination to treat b-cell malignancies
TW202313568A (zh) * 2021-05-21 2023-04-01 大陸商江蘇恒瑞醫藥股份有限公司 Btk抑制劑中間體的製備方法
WO2022261138A1 (en) 2021-06-08 2022-12-15 Tg Therapeutics, Inc. Disrupted ikaros signaling as biomarker for btk inhibition
TW202315615A (zh) * 2021-09-01 2023-04-16 大陸商江蘇恒瑞醫藥股份有限公司 Pi3k抑制劑與btk抑制劑在製備治療淋巴瘤的藥物中的用途
US11814439B1 (en) 2022-06-01 2023-11-14 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11807689B1 (en) 2022-06-01 2023-11-07 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11884740B1 (en) 2022-06-01 2024-01-30 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
CN114751850B (zh) * 2022-06-06 2023-08-25 上海再启生物技术有限公司 一种btk激酶抑制剂关键中间体的制备方法
CN114989062A (zh) * 2022-07-04 2022-09-02 上海再启生物技术有限公司 一种btk激酶抑制剂中间体的晶型及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007266840B2 (en) 2006-05-31 2012-09-20 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Pyrrolo[1,2-A]pyrazin-1(2H)-one and pyrrolo[1,2-D][1,2,4]triazin-1(2H)-one derivatives as inhibitors of poly(ADP-ribose)polymerase(PARP)
KR101315610B1 (ko) * 2006-09-22 2013-10-10 파마시클릭스, 인코포레이티드 브루톤 티로신 키나제 억제제
CA2874756C (en) * 2007-03-28 2018-05-29 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
ES2660418T3 (es) * 2008-07-16 2018-03-22 Pharmacyclics Llc Inhibidores de la tirosina quinasa de Bruton para el tratamiento de tumores sólidos
CA2781056A1 (en) 2009-11-16 2011-05-19 Rebecca Maglathlin Kinase inhibitors
EP2809673B1 (en) * 2012-01-31 2016-11-02 Nanjing Allgen Pharma Co. Ltd. Spirocyclic molecules as bruton's tyrosine kinase inhibitors
JP6175495B2 (ja) 2012-05-31 2017-08-02 ファーマサイエンス・インコーポレイテッドＰｈａｒｍａｓｃｉｅｎｃｅ Ｉｎｃ． プロテインキナーゼ阻害薬
EP2890691B1 (en) * 2012-08-31 2018-04-25 Principia Biopharma Inc. Benzimidazole derivatives as itk inhibitors
US8957080B2 (en) * 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
CN106573001B (zh) * 2014-07-07 2019-01-29 江苏恒瑞医药股份有限公司 作为蛋白激酶抑制剂的氨基哒嗪酮化合物

Also Published As

Publication number Publication date
KR20170023156A (ko) 2017-03-02
CA2953798C (en) 2019-06-11
RU2017103757A3 (es) 2018-08-07
KR102073797B1 (ko) 2020-02-05
PL3166608T3 (pl) 2019-07-31
JP2017522302A (ja) 2017-08-10
ES2706745T3 (es) 2019-04-01
BR112017000470A2 (pt) 2017-11-07
EP3166608A1 (en) 2017-05-17
BR112017000470B1 (pt) 2022-11-29
US20170152264A1 (en) 2017-06-01
CN109970741B (zh) 2020-07-28
CN106573001B (zh) 2019-01-29
CN109970741A (zh) 2019-07-05
TW201625626A (zh) 2016-07-16
US10323037B2 (en) 2019-06-18
AU2014400628B2 (en) 2019-05-02
AU2014400628A1 (en) 2017-01-19
US20180251465A1 (en) 2018-09-06
RU2674701C2 (ru) 2018-12-12
EP3166608B1 (en) 2018-12-12
WO2016007185A1 (en) 2016-01-14
TWI711619B (zh) 2020-12-01
JP6409116B2 (ja) 2018-10-17
EP3166608A4 (en) 2017-11-22
CA2953798A1 (en) 2016-01-14
CN106573001A (zh) 2017-04-19
US9951077B2 (en) 2018-04-24
RU2017103757A (ru) 2018-08-07
ZA201700115B (en) 2020-05-27

Similar Documents

Publication Publication Date Title
MX2017000331A (es) Compuestos de aminopiridazinona como inhibidores de quinasas de proteina.
EP3538548A4 (en) IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
GEP20186887B (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
GEP20207159B (en) Diacylglycerol acyltransferase 2 inhibitors
MX371312B (es) Pirazolil-ureas como inhibidores de quinasas.
PH12016502099A1 (en) 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are jak inhibitors
MX2020003425A (es) Tratamiento de trastornos inflamatorios.
PH12016501107A1 (en) Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
IL269599B1 (en) 11, 13- modified schistosoxins for pain treatment
MX2020003421A (es) Metodos para la administracion de ciertos inhibidores del transportador vesicular de monoamina 2 (vmat2).
MY192927A (en) Fused bicyclic compounds for the treatment of disease
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MX2015000129A (es) Derivados de pirimidin pirazolilo.
PH12016500270A1 (en) Combination of a mek inhibitor and an erk inhibitor for use in treatment of hyperproliferative diseases
GEP20186864B (en) Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders
MX2017008456A (es) Compuestos biciclicos fusionados para el tratamiento de enfermedades.
MX2020006237A (es) Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4.
MX2017004808A (es) Combinaciones que comprenden siponimod y laquinimod para el tratamiento de la esclerosis multiple.
MX2020003483A (es) Composiciones de pienso para animales mejoradas y metodos de uso.
MX2017014456A (es) Usos terapeuticos de l-4-cloroquinurenina.
IL283885A (en) cxcr7 inhibitors for cancer therapy
EP3890750A4 (en) CARBORANE COMPOUNDS, CARBORANE ANALOGUES AND METHODS OF USE THEREOF
GEP201706795B (en) Hexahydrofuropyrroles as pde1 inhibitors
MX2019005294A (es) Inhibidores de las interacciones de mtor-deptor y metodos de uso de los mismos.
EP3574098A4 (en) APPROPRIATE CHEMICAL ENTITIES FOR THERAPY

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: JIANGSU HENGRUI MEDICINE CO., LTD.

FG Grant or registration